Answer
Teprotumumab binds to the insulin-like growth factor-1 receptor (IGF-1R), blocking its activation and signalling, although its mechanism of action in thyroid eye disease has not been fully characterised.
Sources for this answer
- TEPEZZA 500 mg powder for concentrate for solution for infusionAmgen Ltd · emc · SmPC §5.1 Pharmacodynamic properties · Version 1Document updated
Sources checked